Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sumatriptan needle-free injectable - Glide/Endo, Inc.

Drug Profile

Sumatriptan needle-free injectable - Glide/Endo, Inc.

Alternative Names: Glide sumatriptan; GP-01; Sumatriptan SDI

Latest Information Update: 01 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Glide Pharma
  • Developer Endo, Inc.; Glide Technologies
  • Class Antimigraines; Indoles; Small molecules; Sulfonamides; Tryptamines
  • Mechanism of Action Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Migraine

Most Recent Events

  • 23 Apr 2024 Endo International has been acquired and merged into Endo, Inc.
  • 28 Feb 2014 Endo Health Solutions and Paladin Labs combine to form Endo International
  • 17 Mar 2011 Phase-II clinical trials in Migraine in Canada (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top